MedTrace Logo

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

NCT03448978 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-07-01

No results posted yet for this study

Summary

This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.

Conditions

Interventions

BIOLOGICAL

Descartes-08

autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor

DRUG

Fludarabine

intravenous fludarabine

DRUG

Cyclophosphamide

intravenous cyclophosphamide

Sponsors & Collaborators

Principal Investigators

  • Metin Kurtoglu, MD, PhD · Cartesian Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-08
Primary Completion
2021-04-19
Completion
2021-06-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03448978 on ClinicalTrials.gov